Emerging perspectives in proteostasis: bridging mechanisms and therapeutics for human diseases
5 affiliations
- 1Cellular Adaptation and Bioenergetics Group, Institute for Translational Medicine, Medical School Hamburg, Hamburg, Germany
- 2DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany
- 3Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, Heidelberg, Germany
- 4DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany. [email protected]
- 5Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, Heidelberg, Germany. [email protected]
Abstract
Cellular protein homeostasis, or proteostasis, underpins the integrity, adaptability, and survival of all cells by balancing protein synthesis, folding, trafficking, and degradation. This multilayered network is sustained by coordinated actions of molecular chaperones, the ubiquitin‒proteasome system, autophagy-lysosomal pathways, and organelle-specific quality control programs. When this equilibrium collapses, misfolded, aggregated, or damaged proteins accumulate, driving organelle dysfunction, maladaptive stress signaling, and disease progression. Disruption of proteostasis is now recognized as a unifying pathological hallmark linking neurodegenerative disorders, cancer, cardiovascular and metabolic diseases, and autoimmune conditions. This is particularly consequential in post-mitotic organs such as the heart and brain, which possess limited regenerative capacity and are exceptionally vulnerable to proteotoxic stress. Rapid advances now reveal proteostasis as a multicomponent, cross-compartmental, and dynamically adaptable system, rather than isolated pathways. We frame this complexity through the concept of proteostasis resilience, defined as the ability of cells and tissues to maintain proteome stability under stress, and use it to unify disease mechanisms with therapeutic opportunity. This review integrates mechanistic insights with translational advances, outlining how dysregulation of chaperones, autophagy-mitophagy, the ubiquitin‒proteasome system, and ER stress pathways drive human diseases, while highlighting emerging therapeutic platforms, from pharmacological chaperones and autophagy modulators to targeted protein degradation technologies, CRISPR screens, spatial biology, and AI-guided drug discovery. Together, this systems-level perspective positions proteostasis resilience as a foundational paradigm for understanding disease vulnerability and designing precision proteostasis-based therapies.
Related
- Natural Inhibitors of 5-Alpha Reductase: Mechanisms, Therapeutic Potential, and Emerging Perspectives in Androgen-Dependent Prostate Disorders
- Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation
- Pharmaceutical Applications of Nucleic Acid Aptamers: Recent Advances and Future Perspectives in Therapeutics, Biosensing, Bioanalysis, and Process Analysis
- Deciphering the Immune–Bone Interaction Network in Diabetic Bone Fragility: Inflammatory Mechanisms and Precision Therapeutics
- Engineered Microorganisms as GLP-1-Oriented Living Therapeutics for Diabetes and Obesity: Mechanisms and Translational Challenges
BibTeX
@article{borlepawar2026emerging,
title = {{Emerging perspectives in proteostasis: bridging mechanisms and therapeutics for human diseases}},
author = {Ankush Borlepawar and Marco Neu and Ziqi Ma and Anushka Deshpande and Hannah Bühringer and Parvana Hajieva and Norbert Frey and Ashraf Yusuf Rangrez},
journal = {Signal Transduction and Targeted Therapy},
year = {2026},
month = jun,
doi = {10.1038/s41392-026-02714-4},
url = {https://doi.org/10.1038/s41392-026-02714-4},
note = {CC BY},
}
RIS
TY - JOUR
TI - Emerging perspectives in proteostasis: bridging mechanisms and therapeutics for human diseases
AU - Ankush Borlepawar
AU - Marco Neu
AU - Ziqi Ma
AU - Anushka Deshpande
AU - Hannah Bühringer
AU - Parvana Hajieva
AU - Norbert Frey
AU - Ashraf Yusuf Rangrez
PY - 2026
DA - 2026/06/08
JO - Signal Transduction and Targeted Therapy
DO - 10.1038/s41392-026-02714-4
UR - https://doi.org/10.1038/s41392-026-02714-4
AB - Cellular protein homeostasis, or proteostasis, underpins the integrity, adaptability, and survival of all cells by balancing protein synthesis, folding, trafficking, and degradation. This multilayered network is sustained by coordinated actions of molecular chaperones, the ubiquitin‒proteasome system, autophagy-lysosomal pathways, and organelle-specific quality control programs. When this equilibrium collapses, misfolded, aggregated, or damaged proteins accumulate, driving organelle dysfunction, maladaptive stress signaling, and disease progression. Disruption of proteostasis is now recognized as a unifying pathological hallmark linking neurodegenerative disorders, cancer, cardiovascular and metabolic diseases, and autoimmune conditions. This is particularly consequential in post-mitotic organs such as the heart and brain, which possess limited regenerative capacity and are exceptionally vulnerable to proteotoxic stress. Rapid advances now reveal proteostasis as a multicomponent, cross-compartmental, and dynamically adaptable system, rather than isolated pathways. We frame this complexity through the concept of proteostasis resilience, defined as the ability of cells and tissues to maintain proteome stability under stress, and use it to unify disease mechanisms with therapeutic opportunity. This review integrates mechanistic insights with translational advances, outlining how dysregulation of chaperones, autophagy-mitophagy, the ubiquitin‒proteasome system, and ER stress pathways drive human diseases, while highlighting emerging therapeutic platforms, from pharmacological chaperones and autophagy modulators to targeted protein degradation technologies, CRISPR screens, spatial biology, and AI-guided drug discovery. Together, this systems-level perspective positions proteostasis resilience as a foundational paradigm for understanding disease vulnerability and designing precision proteostasis-based therapies.
SN - 2059-3635
SN - 2095-9907
ER -